Case Code : CLMM037
Publication date : 2009
Subject : Marketing Management
Industry : Pharmaceutical
Length : 04 Pages
Price : Rs. 100
To download this case click on the button below, and select the case from the list of available cases:
Pharmaceutical marketing, personalized medicine, blockbuster drug, blockbuster model, drug development, product pipeline, targeted marketing. niche, ethics, Pfizer, Merck, Lipitor, Vioxx, Torcetrapib, NitroMed BiDil
1: This caselet is intended for use only in class discussions.
2: More comprehensive case studies are priced at Rs.200 to Rs.700 (US $5 to US $16) per copy.
In 2007, Apple Inc. raised many eyebrows by reducing the price of its much hyped iPhone by one-third within 10 weeks of the launch. While some analysts felt that adoption of such market skimming strategies and subsequent price cuts by companies selling technological devices was nothing new, others felt that Apple's decision to reduce the price so drastically just a few weeks after the launch was a public relations fiasco. As a section of the early adopters of iPhone voiced their resentment, Apple went into damage-control mode.
Questions for Discussion:
1. What, according to you, are the reasons for the increased interest in personalized medicine? Do you agree with analysts that the era of blockbuster drugs is over? Give reasons for you answer.
2. Do you agree with analysts that the arrival of personalized medicine would change the rules of pharmaceutical marketing? If so, in what way would the marketing of personalized medicine differ from that of the other pharmaceutical drugs?
3. Discuss the ethical issues surrounding the development and marketing of personalized medicine. Consider yourself a person is charge of marketing one of the first personalized medicine brands. What actions would you take to ensure the successful launch of the brand considering that you expect the launch of the drug to spur a hot of debate on the ethics of marketing a personalized medicine?
Cases on related topics